ATC Group: L01AD01 Carmustine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01AD01 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01A Alkylating agents
4 L01AD Nitrosoureas
5 L01AD01 Carmustine

Active ingredients in L01AD01

Active Ingredient

Carmustine is a cell-cycle phase nonspecific antineoplastic agent of the nitrosourea type. As an alkylating agent, it can alkylate reactive sites on nucleoproteins, thus interfering with DNA and RNA synthesis and DNA repair. In addition, carmustine is known to carbamoylate lysine residues on proteins causing irreversible inactivation of enzymes including glutathione reductase.

Related product monographs

Document Type Information Source  
 GLIADEL Implant MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Estonia (EE)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

New Zealand (NZ)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.